Research Brief
Tirzepatide: Research Overview
An approved dual GIP/GLP-1 receptor agonist (Mounjaro / Zepbound) for type 2 diabetes and weight management — supplied here as research-grade material for laboratory use only, not the approved medicine.
Last reviewed: June 2, 2026
For Laboratory Research Use Only
Content on this page describes published research findings. LUMEN BASED does not make therapeutic claims. Consult the primary literature and your institutional review board for protocol design. These products are not for human consumption.
What is Tirzepatide?
Tirzepatide is a dual GIP and GLP-1 receptor co-agonist — it activates two gut-hormone receptors at once. Like semaglutide, it is an approved prescription medicine (Mounjaro for type 2 diabetes; Zepbound for chronic weight management). Reviews describe "unmatched effectiveness" on glycemic control and weight versus prior single-agonist drugs. [Nauck 2022]
What the published clinical research found
Type 2 diabetes (SURPASS-1)
In 478 patients, tirzepatide reduced HbA1c by about 1.87–2.07% (versus +0.04% with placebo); 87–92% reached HbA1c below 7.0%, with 7.0–9.5 kg weight loss and mild-to-moderate gastrointestinal effects. [Rosenstock 2021]
Weight management (SURMOUNT-2)
In 938 adults with obesity and type 2 diabetes, tirzepatide 10/15 mg achieved −12.8% / −14.7% body weight versus −3.2% with placebo over 72 weeks. [Garvey 2023]
Maintenance (SURMOUNT-4)
Continuing tirzepatide preserved weight loss (about 20.9% initial reduction), while switching to placebo led to a +14.0% rebound. [Aronne 2024]
Cardiovascular safety
A pre-specified meta-analysis of seven SURPASS trials found no increased risk of major adverse cardiovascular events (hazard ratio 0.80). [Sattar 2022]
Mechanism
Tirzepatide reduced appetite, energy intake, and fat mass, with greater fat-mass loss than semaglutide 1 mg — suggesting mechanisms beyond appetite suppression. [Heise 2023]
Regulatory status & research-use only
Tirzepatide is an approved prescription medication available only through licensed healthcare providers (Mounjaro, Zepbound). LUMEN BASED supplies tirzepatide strictly as a research-grade material for laboratory use only. It is not the approved pharmaceutical product, is not intended for human or veterinary use, and nothing on this page is medical advice, a prescription, or a recommendation to use it. Anyone considering treatment should consult a licensed physician. Every reference below links to its primary source on PubMed for independent verification.
Verify the batch you're studying
Each Tirzepatide lot ships with a third-party Certificate of Analysis (HPLC, mass spectrometry, identity confirmation). Pair the batch in your study with the matching COA before publishing or reporting results.
View COA for Tirzepatide →References
- Nauck MA et al. (2022). Tirzepatide, a dual GIP/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction. PubMed
- Rosenstock J et al. (2021). Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1). PubMed
- Garvey WT et al. (2023). Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). PubMed
- Aronne LJ et al. (2024). Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. PubMed
- Sattar N et al. (2022). Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. PubMed
- Heise T et al. (2023). Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes. PubMed
For Research Use Only. All LUMEN BASED compounds are strictly for in vitro laboratory research by qualified researchers. Not for human or animal consumption. Not approved by the FDA for therapeutic use.